ヨーロッパの前立腺癌診断および治療市場調査レポート : 2027年までの予測

出版:Market Research Future(マーケットリサーチフューチャー) 出版年月:2023年 1月

Europe Prostate Cancer Diagnosis and Therapy Market Research Report Forecast to 2027
ヨーロッパの前立腺癌診断および治療市場調査レポート : 2027年までの予測

ページ数 128
価格
シングルユーザライセンス USD2,950
エンタープライズライセンス USD5,250
種別 英文調査報告書

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

Europe Prostate Cancer Diagnosis and Therapy Market Research Report Forecast to 2027
Market Overview
The Europe prostate cancer diagnosis and therapy market was valued at USD 4,002.70 million in 2020 and is expected to register a CAGR of 5.05% during the assessment period. Prostate cancer is a type of cancer that affects only males in the prostate gland cells and is highly treatable in the early stages. There are various approaches to diagnose and treat prostate cancer available in the market.
The Europe prostate cancer diagnosis and therapy market is emerging due to the rising prevalence rate of prostate cancer. The increasing expenditure on oncology medicine research is anticipated to drive the growth of the market during the forecast period. Additionally, the launching of new products will provide growth opportunities for the market in the future. However, the side effects of Therapy and shortage of skilled and experienced oncologists might hamper the market’s growth in the forecast period.
Market Segmentation
Based on stage, the Europe prostate cancer diagnosis and therapy market is segmented into stage I, stage II, stage III, and stage IV. The Europe prostate cancer diagnosis and therapy market is driven due to the increasing consumption of oncogene-activating components such as tobacco and unhealthy lifestyle. Stage II held the largest market in 2020
Based on type, the Europe prostate cancer diagnosis and therapy market is segmented into prostatic adenocarcinoma, small cell carcinoma, and others. The other segment includes squamous cell carcinoma, neuroendocrine tumors, soft tissue sarcoma, and transitional cancer. Prostatic adenocarcinoma holds the largest market size owing to a large patient pool. The other factor contributing to the increase in prostatic cases are aging, smoking, and obesity.
In terms of components, the Europe prostate cancer diagnosis and therapy market is segmented into diagnosis and therapy. The diagnosis segment is further sub-segmented into tissue biopsy, diagnostic imaging, and others. The therapy segment is sub-segmented into chemotherapy, hormonal therapy, and immunotherapy. The diagnostic imaging segment is expected to hold the largest market size by diagnosis method during the forecast period. The Europe prostate cancer diagnosis and therapy market based on end user has been segmented into hospitals & clinics, specialty centers, and others. The others segment includes ambulatory surgical centers and research institutions.
Regional Analysis
The growing aging population, rising prevalence rate of prostate cancer across Europe, and the increasing awareness among the individuals coupled with the various government initiatives to promote the Therapy of prostate cancer in the early stages are some of the prominent factors driving the growth of the Europe prostate cancer diagnosis and therapy market. For instance, as per GLOBOCAN, in 2020, Europe reported 518.11 new prostate cancer cases per 100,000 population. Similarly, according to the European Alliance for Personalized Medicine, the number of men being diagnosed with prostate cancer in Europe has increased over recent years.
Major Players
The market players include Astellas Pharma, Inc., Johnson & Johnson Services, Inc, Bayer AG, Roche Holding AG, Ipsen S.A., Tolmar Inc., Ferring B.V., and Esaote Spa.
Indonesia Geothermal Power Market Research Report Forecast to 2030

Market Overview
Indonesia geothermal power market was valued at USD 231.15 million in 2020 and is expected to register a CAGR of 7.62% to reach USD 469.90 million by the end of 2030. Geothermal power is electricity generated from geothermal energy, in which steam from underground hot water is used to rotate a turbine, which is then connected to a generator to produce electricity. It is an energy source derived from the earth’s inner heat and is relatively environmentally friendly. The Indonesia geothermal power market is expected to register healthy growth during the review period due to the increased demand for clean energy generation to minimize reliability on fossil fuels for power. Furthermore, the rising demand for power across various end-use sectors is also expected to contribute to the growth of the Indonesia geothermal power market during the forecast period. However, high capital requirements associated with geothermal are expected to restrain the growth of the Indonesia geothermal power market during the forecast period. Nevertheless, favorable government policies and regulations are expected to create lucrative opportunities for vendors in the Indonesia geothermal market.
The key factor driving the growth of the Indonesia geothermal power market is increased demand for clean energy generation to minimize reliability on fossil fuels for power. Furthermore, the rising demand for power across various end-use sectors is also expected to contribute to the growth of the Indonesia geothermal power market during the forecast period. However, high capital requirements associated with geothermal are expected to restrain the growth of the Indonesia geothermal power market during the forecast period.
Market Overview
Indonesia geothermal power market has been segmented by power plant type, power output, and end-use. Based on power plant type, the market has been segmented into flash steam plants, dry steam plants, and binary cycle power plants.
Based on power output, the market has been segmented into up to 5 MW and above 5 MW. The above 5 MW segment accounted for the largest share, with 89.41% of the Indonesia geothermal power market.
Based on end-use, the market has been segmented into commercial, residential, and industrial. The industrial segment accounted for the largest share of 44.05% .

Major Players
The key players in the market are PT Pertamina, Sarulla Operations Limited, Enel Green Power S.p.A., Toshiba Energy Systems & Solutions Corporation, BCPG Public Company Limited, PT. Supreme Energy, Berkshire Hathaway Energy, Sumitomo Corporation, Ansaldo Energia S.p.A., Fuji Electric Co., Ltd., Mitsubishi Gas Chemical Company, Chevron Corporation, and others.

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.


目次

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING PREVALENCE RATE OF PROSTATE CANCER
4.2.2 INCREASING EXPENDITURE ON ONCOLOGY MEDICINE AND RESEARCH
4.3 RESTRAINTS
4.3.1 SIDE-EFFECTS OF THERAPY
4.3.2 SHORTAGE OF SKILLED AND EXPERIENCED ONCOLOGIST
4.4 OPPORTUNITY
4.4.1 LAUNCH OF INNOVATIVE THERAPY PRODUCTS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PATIENTS SUFFERING FROM PROSTATE CANCER
5.3.3 IMPACT ON PRICING
5.3.4 IMPACT ON CLINICAL TRIALS
6 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES
6.1 OVERVIEW
6.2 STAGE I
6.3 STAGE II
6.4 STAGE III
6.5 STAGE IV
7 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE
7.1 OVERVIEW
7.2 PROSTATIC ADENOCARCINOMA
7.3 SMALL CELL CARCINOMA
7.4 OTHERS
8 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT
8.1 OVERVIEW
8.2 THERAPY
8.2.1 HORMONAL THERAPY
8.2.2 CHEMOTHERAPY
8.2.3 RADIOTHERAPY DRUGS
8.2.4 IMMUNOTHERAPY
8.2.5 OTHERS
8.3 DIAGNOSIS
8.3.1 DIAGNOSTIC IMAGING
8.3.2 TISSUE BIOPSY
8.3.3 OTHERS
9 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER
9.1 OVERVIEW
9.2 SPECIALTY CENTERS
9.3 HOSPITALS & CLINICS
9.4 OTHERS
10 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY REGION/COUNTRY
10.1 OVERVIEW
10.2 WESTERN EUROPE
10.2.1 GERMANY
10.2.2 FRANCE
10.2.3 UK
10.2.4 ITALY
10.2.5 SPAIN
10.2.6 REST OF WESTERN EUROPE
10.3 EASTERN EUROPE
10.3.1 HUNGARY
10.3.2 POLAND
10.3.3 RUSSIA
10.3.4 REST OF EASTERN EUROPE
10.4 REST OF EUROPE
11 COMPETITIVE LANDSCAPE
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
11.6.2 EXPANSION
11.7 FINANCIAL MATRIX
11.7.1 SALES (USD MILLION), 2020
11.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020
12 COMPANY PROFILES
12.1 ABBVIE INC.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 PRODUCTS/SERVICES OFFERED
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 ASTRAZENECA
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 BAYER AG
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 SANOFI
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 IPSEN S.A.
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 ASTELLAS PHARMA INC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 FERRING PHARMACEUTICALS
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS/SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 TOLMAR PHARMACEUTICALS, INC.
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 JOHNSON & JOHNSON SERVICES INC.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 ESAOTE SPA
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
12.11 F. HOFFMANN-LA ROCHE LTD
12.11.1 COMPANY OVERVIEW
12.11.2 FINANCIAL OVERVIEW
12.11.3 PRODUCTS/SERVICES OFFERED
12.11.4 KEY DEVELOPMENTS
12.11.5 SWOT ANALYSIS
12.11.6 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 4 STAGES OF PROSTATE CANCER WITH GLEASON SCORE AND PROSTATE-SPECIFIC ANTIGEN LEVELS
TABLE 5 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR STAGE I, BY REGION, 2018–2027 (USD MILLION)
TABLE 6 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR STAGE II, BY REGION, 2018–2027 (USD MILLION)
TABLE 7 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR STAGE III, BY REGION, 2018–2027 (USD MILLION)
TABLE 8 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR STAGE IV, BY REGION, 2018–2027 (USD MILLION)
TABLE 9 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 10 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR PROSTATIC ADENOCARCINOMA, BY REGION, 2018–2027 (USD MILLION)
TABLE 11 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR SMALL CELL CARCINOMA, BY REGION, 2018–2027 (USD MILLION)
TABLE 12 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 13 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 14 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR THERAPY, BY REGION, 2018–2027 (USD MILLION)
TABLE 15 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 16 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 17 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 18 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR DIAGNOSIS, BY REGION, 2018–2027 (USD MILLION)
TABLE 19 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 20 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 21 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR SPECIALITY CENTERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 22 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2018–2027 (USD MILLION)
TABLE 23 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 24 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY REGION, 2018–2027 (USD MILLION)
TABLE 25 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 26 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 27 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 28 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 29 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 30 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 31 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 32 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 33 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY WESTERN COUNTRY, 2017–2027 (USD MILLION)
TABLE 34 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 35 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 36 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 37 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 38 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 39 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 40 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 41 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 42 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 43 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 44 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 45 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 46 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 47 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 48 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 49 GERMANY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 50 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 51 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 52 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 53 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 54 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 55 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 56 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 57 FRANCE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 58 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 59 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 60 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 61 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 62 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 63 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 64 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 65 UK: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 66 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 67 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 68 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 69 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 70 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 71 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 72 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 73 ITALY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 74 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 75 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 76 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 77 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 78 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 79 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 80 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 81 SPAIN: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 82 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 83 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 84 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 85 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 86 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 87 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 88 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 89 REST OF WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 90 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY EASTERN COUNTRY, 2017–2027 (USD MILLION)
TABLE 91 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 92 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 93 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 94 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 95 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 96 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 97 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 98 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 99 HUNGARY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 100 HUNGARY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 101 HUNGARY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 102 HUNGARY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 103 HUNGARY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 104 HUNGARY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 105 HUNGARY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 106 HUNGARY: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 107 POLAND: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 108 POLAND: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 109 POLAND: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 110 POLAND: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 111 POLAND: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 112 POLAND: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 113 POLAND: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 114 POLAND: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 115 RUSSIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 116 RUSSIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 117 RUSSIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 118 RUSSIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 119 RUSSIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 120 RUSSIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 121 RUSSIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 122 RUSSIA: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 123 REST OF EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 124 REST OF EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 125 REST OF EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 126 REST OF EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 127 REST OF EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 128 REST OF EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 129 REST OF EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 130 REST OF EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 131 REST OF EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 132 REST OF EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 133 REST OF EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2018–2027 (USD MILLION)
TABLE 134 REST OF EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 135 REST OF EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR HORMONAL THERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 136 REST OF EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR CHEMOTHERAPY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 137 REST OF EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET FOR DIAGNOSIS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 138 REST OF EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 139 MAJOR PLAYERS IN THE GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET
TABLE 140 MOST ACTIVE PLAYERS IN THE GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET
TABLE 141 PRODUCT LAUNCH/PRODUCT APPROVAL
TABLE 142 EXPANSION
TABLE 143 ABBVIE INC.: PRODUCTS OFFERED
TABLE 144 ABBVIE INC.: PRODUCTS OFFERED
TABLE 145 ASTRAZENECA: PRODUCTS/SERVICES OFFERED
TABLE 146 ASTRAZENECA: KEY DEVELOPMENTS
TABLE 147 BAYER AG: PRODUCTS/SERVICES OFFERED
TABLE 148 BAYER AG: KEY DEVELOPMENTS
TABLE 149 SANOFI: PRODUCTS/SERVICES OFFERED
TABLE 150 IPSEN S.A.: PRODUCTS/SERVICES OFFERED
TABLE 151 IPSEN S.A.: KEY DEVELOPMENTS
TABLE 152 ASTELLAS PHARMA INC.: PRODUCTS/SERVICES OFFERED
TABLE 153 ASTELLAS PHARMA INC.: KEY DEVELOPMENTS
TABLE 154 FERRING PHARMACEUTICALS.: PRODUCTS/SERVICES OFFERED
TABLE 155 TOLMAR PHARMACEUTICALS, INC: PRODUCTS/SERVICES OFFERED
TABLE 156 JOHNSON & JOHNSON SERVICES INC. PRODUCTS/SERVICES OFFERED
TABLE 157 ESAOTE SPA: PRODUCTS/SERVICES OFFERED
TABLE 158 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 MARKET STRUCTURE: EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET
FIGURE 9 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES, 2020 & 2027 (USD MILLION)
FIGURE 10 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE, 2020 & 2027 (USD MILLION)
FIGURE 11 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT, 2020 & 2027 (USD MILLION)
FIGURE 12 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER, 2020 & 2027 (USD MILLION)
FIGURE 13 EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE, BY REGION 2020 (%)
FIGURE 14 WESTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE, BY REGION 2020 (%)
FIGURE 15 EASTERN EUROPE: PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET SHARE, BY REGION 2020 (%)
FIGURE 16 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 17 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET
FIGURE 18 GLOBAL PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET: COMPETITIVE LANDSCAPE
FIGURE 19 SALES (USD MILLION), 2020
FIGURE 20 RESEARCH & DEVELOPMENT EXPENDITURE 2020
FIGURE 21 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 ABBVIE INC.: SWOT ANALYSIS
FIGURE 23 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 ASTRAZENECA: SWOT ANALYSIS
FIGURE 25 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 BAYER AG: SWOT ANALYSIS
FIGURE 27 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 SANOFI: SWOT ANALYSIS
FIGURE 29 IPSEN S.A.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 IPSEN S.A.: SWOT ANALYSIS
FIGURE 31 ASTELLAS PHARMA INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 ASTELLAS PHARMA INC.: SWOT ANALYSIS
FIGURE 33 FERRING PHARMACEUTICALS.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 FERRING PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 35 TOLMAR PHARMACEUTICALS, INC.: SWOT ANALYSIS
FIGURE 36 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS
FIGURE 38 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS


    お問合せフォーム

    • レポートのタイトルは自動で入ります。

    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com